本报告描述了作者进行 150 例连续机器人胰十二指肠切除术的经验。该研究连续招募了 150 名在 2018 年至 2023 年间接受机器人胰十二指肠切除术的患者。术前和术中变量，如年龄、性别、适应症、手术时间、诊断和肿瘤大小分析了。患者被分为两组。第 1 组包括前 75 名患者，第 2 组包括最后 75 名患者。患者的中位年龄为 62.4 岁，两组之间没有差异。第 2 组的发病率较低。30 天时的死亡率为 0.7%，90 天时的死亡率为 1.3%，两组之间没有差异。第 2 组的手术时间、切除时间、重建时间和中转开腹手术均显着减少 (p < 0.05)。 17 例患者进行了门静脉部分切除，第 2 组更为常见 (p < 0.01) ）。第 2 组切除的淋巴结数量较多。两组间胰十二指肠切除术的指征没有差异。患者的肿瘤大小或临床特征没有差异。机器人平台可用于胰十二指肠切除术，有助于充分的淋巴结清扫，并有助于切除后的消化道重建。机器人胰十二指肠切除术对于选定的患者来说是安全可行的。它应该由在开放式和微创胰腺手术方面经验丰富的外科医生在专门中心进行。© 2024。外科肿瘤学会。

This report describes the authors' experience with 150 consecutive robotic pancreatoduodenectomies.The study enrolled 150 consecutive patients who underwent robotic pancreatoduodenectomy between 2018 and 2023. Pre- and intraoperative variables such as age, gender, indication, operation time, diagnosis, and tumor size were analyzed. The patients were divided into two groups. Group 1 comprised the first 75 patients, and group 2 comprised the last 75 cases. The median age of the patients was 62.4 years and did not differ between the two groups.Morbidity was lower in group 2. The mortality rate was 0.7% at 30 days and 1.3% at 90 days, and there was no difference between the groups. There was a significant reduction (p < 0.05) in operative time, resection time, reconstruction time, and conversion to open surgery in group 2. Partial resection of the portal vein was performed in 17 patients and more common in group 2 (p < 0.01). The number of resected lymph nodes was higher in group 2. The indication for pancreatoduodenectomy did not differ between the two groups. There was no difference in tumor size or clinical characteristics of the patients.The robotic platform is useful for pancreatoduodenectomy, facilitates adequate lymphadenectomy, and is helpful for digestive tract reconstruction after resection. Robotic pancreatoduodenectomy is safe and feasible for selected patients. It should be performed in specialized centers by surgeons experienced in open and minimally invasive pancreatic surgery.© 2024. Society of Surgical Oncology.